Thanks for sharing, at least with the context of your comments each investor can make their own informed opinion on the weight to place on the information.
I have no concerns at all and strongly maintain my sentiment of Buy.
Current SP is undervalued IMO, similar to how it was at $8 vs the information available only 12 months ago.
I see a lot of positive on the horizon with partnerships, test results, NAZDAQ, approvals etc. - As the results come in, marketing continues, and the valve is sold under category B, more and more surgeons around the world will hear about and be recommending DurAVR (don't forget Adapt).
Good luck to all - To the Moon!
Cardiology, page-22
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |